A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours

Trial Profile

A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs WX 554 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors WILEX AG
  • Most Recent Events

    • 28 Sep 2016 Results of this trial, published in the European Journal of Cancer.
    • 14 Apr 2014 Status changed from recruiting to discontinued, as reported in a Wilex media release.
    • 28 Feb 2013 Wilex anticipates that recruitment will be completed by the end of 2013 and results will be presented in the second half of 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top